Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04445285 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure
A Phase 2 study of Covid19, sponsored by Jon Simmons.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
- 1
- Study location
NCT04445285 is a Phase 2 study of Covid19 that is actively recruiting participants, run by Jon Simmons. The registered enrollment target is 44 participants, below the 2,702-participant average among 94 other Covid19 trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04445285, a Phase 2 study of Covid19, is actively recruiting participants, sponsored by Jon Simmons.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
This Phase 2 Randomized Placebo Controlled Trial will determine if administering nebulized Dornase Alpha (rhDNase) to COVID-19 patients with respiratory failure is safe and will reduce 28-day mortality.
Conditions Studied
Interventions
- DRUG Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase)
- DRUG 0.9%sodium chloride
Study Locations (1)
Alabama
- University of South Alabama - Mobile
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2020-04-28 |
| Est. Completion | 2022-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04445285
The ClinicalTrials.gov registry entry for NCT04445285 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,702-participant average among 94 other Covid19 trials with a reported enrollment target (98% lower). The listed sponsor is Jon Simmons, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Covid19 appearing as the primary indexed condition, and to 2 interventions - of which Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase) is the first listed.
NCT04445285 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT04445285 about?
NCT04445285 is a clinical study titled "Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure". This Phase 2 Randomized Placebo Controlled Trial will determine if administering nebulized Dornase Alpha (rhDNase) to COVID-19 patients with respiratory failure is safe and will reduce 28-day mortality.
What is the current status of trial NCT04445285?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2020-04-28. Estimated completion is 2022-02-28.
What conditions does trial NCT04445285 study?
This clinical trial studies the following conditions: Covid19.
What interventions are being tested in trial NCT04445285?
The interventions under investigation include: Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase) (DRUG), 0.9%sodium chloride (DRUG).
Who is sponsoring clinical trial NCT04445285?
This trial is sponsored by Jon Simmons, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04445285 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Covid19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Imaging Immune Activation in COVID-19
RECRUITING · Phase 2
-
Defibrotide for the Treatment of Severe COVID-19
RECRUITING · Phase 2
-
SARS-Cov-2 (COVID-19) Nasal Pharyngeal and Oral Pharyngeal Wash (SNOW) Trial
ACTIVE NOT RECRUITING · Phase 2
-
COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation
ACTIVE NOT RECRUITING · Phase 2
-
A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults
ACTIVE NOT RECRUITING · Phase 2
-
Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.